The Role of Aspirin Resistance in the Treatment of Acute Coronary Syndromes
| Autor: | Hitender Jain, Gilead Lancaster, Stuart Zarich |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Acute coronary syndrome
medicine.medical_specialty medicine.drug_class Drug Resistance Reviews Low molecular weight heparin Coronary Disease Internal medicine medicine Humans Risk factor Thrombus Aspirin Framingham Risk Score business.industry Syndrome General Medicine Heparin medicine.disease Surgery Treatment Outcome Acute Disease Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors TIMI medicine.drug |
| Zdroj: | Clinical Cardiology. 31:11-17 |
| ISSN: | 1932-8737 0160-9289 |
| Popis: | The TIMI Risk Score recognizes prior aspirin use as an independent risk factor for adverse outcomes in subjects presenting with an acute coronary syndrome. The etiology of this increased risk awaits clarification, but prior aspirin use may be associated with altered thrombus composition which is more resistant to current treatment modalities as compared to thrombus formation in subjects without prior aspirin use. Post hoc analysis of acute coronary syndrome trials has shown that prior aspirin users treated with unfractionated heparin are at particularly high risk. The addition of glycoprotein IIb/IIIa receptor inhibitor to unfractionated heparin or substitution of low‐molecular‐weight heparin significantly improves outcomes in prior aspirin users. The prognostic significance of prior aspirin use in acute coronary syndromes has important implications not only in clinical practice, but also in the design and interpretation of clinical trials. Copyright © 2007 Wiley Periodicals, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|